Keywords: |
aged; aged, 80 and over; excision; primary tumor; case report; treatment duration; antineoplastic agents; cancer radiotherapy; combined modality therapy; lymph node dissection; adenocarcinoma; t lymphocyte; prostate specific antigen; dacarbazine; melanoma; multiple cycle treatment; skin neoplasms; tumor markers, biological; tumor antigen; docetaxel; cancer hormone therapy; gleason score; prostate-specific antigen; prostatic neoplasms; leuprorelin; prostate specific membrane antigen; immunotherapy; antigens, neoplasm; psa; gefitinib; brain metastasis; neoplasm metastasis; remission; autoimmunity; taxoids; prostate adenocarcinoma; neoplasms, second primary; graft rejection; bicalutamide; hydrocortisone; ketoconazole; trastuzumab; fatal outcome; neovascularization (pathology); everolimus; antibodies, neoplasm; antibody production; bone scintiscanning; glutamate carboxypeptidase ii; geldanamycin; psma; metastatic prostate cancer
|